Zoetis Inc (NYSE:ZTS) — Market Cap & Net Worth
Market Cap & Net Worth: Zoetis Inc (ZTS)
Zoetis Inc (NYSE:ZTS) has a market capitalization of $35.23 Billion ($35.23 Billion) as of June 17, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #771 globally and #350 in its home market, demonstrating a 0.64% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zoetis Inc's stock price $79.95 by its total outstanding shares 440693214 (440.69 Million). Review Zoetis Inc balance sheet liabilities to assess the company's total debt and financial obligations.
Zoetis Inc Market Cap History: 2015 to 2026
Zoetis Inc's market capitalization history from 2015 to 2026. Data shows growth from $19.78 Billion to $35.23 Billion (6.48% CAGR).
Index Memberships
Zoetis Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Pharmaceutical
DRG
|
$3.26 Trillion | 1.08% | #11 of 24 |
|
S&P 500 Index
GSPC
|
$62.29 Trillion | 0.15% | #262 of 503 |
Weight: Zoetis Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Zoetis Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zoetis Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
7.76x
Zoetis Inc's market cap is 7.76 times its annual revenue
Latest Price to Earnings (P/E) Ratio
28.88x
Zoetis Inc's market cap is 28.88 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $19.78 Billion | $4.76 Billion | $339.00 Million | 4.15x | 58.36x |
| 2016 | $22.28 Billion | $4.89 Billion | $821.00 Million | 4.56x | 27.14x |
| 2017 | $30.21 Billion | $5.31 Billion | $864.00 Million | 5.69x | 34.96x |
| 2018 | $36.08 Billion | $5.83 Billion | $1.43 Billion | 6.19x | 25.27x |
| 2019 | $56.18 Billion | $6.26 Billion | $1.50 Billion | 8.97x | 37.45x |
| 2020 | $70.66 Billion | $6.67 Billion | $1.64 Billion | 10.59x | 43.14x |
| 2021 | $104.76 Billion | $7.78 Billion | $2.04 Billion | 13.47x | 51.43x |
| 2022 | $63.37 Billion | $8.08 Billion | $2.11 Billion | 7.84x | 29.98x |
| 2023 | $86.13 Billion | $8.54 Billion | $2.34 Billion | 10.08x | 36.74x |
| 2024 | $71.80 Billion | $9.26 Billion | $2.49 Billion | 7.76x | 28.88x |
Competitor Companies of ZTS by Market Capitalization
Companies near Zoetis Inc in the global market cap rankings as of June 17, 2026.
Key companies related to Zoetis Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #512 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #560 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #613 globally with a market cap of $44.69 Billion USD ( CN¥305.43 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #629 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #512 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #560 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.41 |
| #613 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.69 Billion | CN¥47.88 |
| #629 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
Zoetis Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Zoetis Inc's market cap moved from $19.78 Billion to $ 35.23 Billion, with a yearly change of 6.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $35.23 Billion | -36.46% |
| 2025 | $55.45 Billion | -22.78% |
| 2024 | $71.80 Billion | -16.63% |
| 2023 | $86.13 Billion | +35.91% |
| 2022 | $63.37 Billion | -39.51% |
| 2021 | $104.76 Billion | +48.26% |
| 2020 | $70.66 Billion | +25.76% |
| 2019 | $56.18 Billion | +55.71% |
| 2018 | $36.08 Billion | +19.45% |
| 2017 | $30.21 Billion | +35.55% |
| 2016 | $22.28 Billion | +12.64% |
| 2015 | $19.78 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of Zoetis Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $35.23 Billion USD |
| MoneyControl | $35.23 Billion USD |
| MarketWatch | $35.23 Billion USD |
| marketcap.company | $35.23 Billion USD |
| Reuters | $35.23 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zoetis Inc
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and… Read more